XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2

Collaborations and Other Arrangements (Details) $ / shares in Units, $ in Thousands, € in Millions						1 Months Ended	3 Months Ended						9 Months Ended		12 Months Ended
	Aug. 02, 2022 EUR (€)	Apr. 16, 2021 USD ($) $ / shares shares	Feb. 01, 2021 USD ($) item	Jan. 13, 2020 USD ($)	Nov. 04, 2019 EUR (€)	Mar. 31, 2022 USD ($)	Sep. 30, 2022 USD ($) $ / shares	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2019 EUR (€)	Dec. 31, 2021 USD ($) $ / shares	Apr. 14, 2020 $ / shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Research and development							$ 45,808		$ 54,085				$ 170,336	$ 312,343
Accounts payable							9,917						9,917				$ 16,159
Accrued and other current liabilities							$ 85,990						$ 85,990				$ 48,127
License Agreement Fee						$ 35,000
Common Stock Par Or Stated Value Per Share | $ / shares							$ 0.0001						$ 0.0001				$ 0.0001
Share Price | $ / shares							$ 9.61						$ 9.61					$ 14.815
Bioeq IP AG
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Initial term of agreement					10 years
Percentage of gross profits shared					50.00%
Bioeq IP AG | Licensed Products
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Maximum aggregate milestone payments | €					€ 12.5
Additional milestone payments related to FDA approval | €	€ 2.5
Bioeq IP AG | Research and Development Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Upfront and milestone payment															$ 11,100	€ 10.0
Innovent Biologics (Suzhou) Co., Ltd.
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Research and development									500					1,200
Innovent Biologics (Suzhou) Co., Ltd. | Bevacizumab Licensed Product
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Collaboration Agreement, upfront amount paid				$ 5,000
Maximum aggregate milestone payments				40,000
Innovent Biologics (Suzhou) Co., Ltd. | Rituxan option
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Maximum aggregate milestone payments				$ 40,000
Collaboration Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions
License Agreement Fee			$ 35,000
Collaboration Agreement | Anti-TIGIT Antibody and IL-2 cytokine
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Collaboration Agreement , Maximum Payments On Attainment Of Certain Sales Thresholds For Each Option Program						$ 170,000		$ 170,000
Collaboration Agreement | Research and Development Expense | Anti-TIGIT Antibody and IL-2 cytokine
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Collaboration Agreement, upfront amount paid								$ 35,000
Junshi Biosciences
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Maximum paid amount for co-development activities (per licensed compound)			$ 25,000
Collaboration Agreement, upfront amount paid												$ 5,000
Research and development							$ 7,600		$ 15,400				$ 67,600	$ 173,600
Undisclosed preclinical | item			2
Collaboration agreement, royalty on net sales for each exercised option, percentage			18.00%
Collaboration agreement, Maximum aggregate one-time payment for achievement of milestones, for each option program			$ 85,000
Share Price | $ / shares		$ 20.06
Unregistered shares | shares		2,491,988
Aggregate value		$ 50,000
Period before the company can sell, transfer or make any short sale of common stock (in years)		2 years
Fair value for the discount for lack of marketability (DLOM)		$ 9,000
Junshi Biosciences | Accrued and other current liabilities
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Co-development, regulatory and technology transfer costs							$ 17,500						$ 17,500
Junshi Biosciences | Toripalimab
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Collaboration Agreement, upfront amount paid			$ 150,000
Collaboration agreement, royalty on net sales, percentage			20.00%
Collaboration agreement, threshold royalty payments			$ 380,000
Junshi Biosciences | Research and Development Expense | Toripalimab
Collaborative Arrangements And Noncollaborative Arrangement Transactions
Collaboration Agreement, upfront amount paid										$ 9,000	$ 145,000

X

- Definition

Additional milestone payments upon achievement of certain development and regulatory milestones.

+ References

No definition available.

+ Details

Name:	chrs_AdditionalMilestonePaymentsUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Additional milestone payments upon achievement of with subject to FDA approval

+ References

No definition available.

+ Details

Name:	chrs_AdditionalMilestonePaymentsUponAchievementWithSubjectToFdaApproval
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents co-development, regulatory and technology transfer costs.

+ References

No definition available.

+ Details

Name:	chrs_CoDevelopmentRegulatoryAndTechnologyTransferCosts
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The amount of maximum payments to be made on attainment of certain sales thresholds for each option program under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementMaximumPaymentsOnAttainmentOfCertainSalesThresholdsForEachOptionProgram
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Number of undisclosed preclinical immuno-oncology drug candidates under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementNumberOfUndisclosedPreclinicalImmunoOncologyDrugCandidates
Namespace Prefix:	chrs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of option exercise fee per program under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementOptionExerciseFeePerProgram
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the percentage of royalty on net sales under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSales
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of royalty on net sales for each option program under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementPercentageOfRoyaltyOnNetSalesForEachOptionProgram
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of threshold payments to be made on achievement on various milestones for each option program under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementThresholdPaymentsOnAchievementOfVariousMilestoneForEachOptionProgram
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The amount of threshold royalty payments to be made under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationAgreementThresholdRoyaltyPayments
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents costs associated to a collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_CollaborationCosts
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the fair value for the discount for lack of marketability (DLOM).

+ References

No definition available.

+ Details

Name:	chrs_FairValueForDiscountForLackOfMarketability
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Initial term of agreement.

+ References

No definition available.

+ Details

Name:	chrs_InitialTermOfAgreement
Namespace Prefix:	chrs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the maximum paid amount for co-development activities.

+ References

No definition available.

+ Details

Name:	chrs_MaximumAmountPaidCoDevelopmentActivities
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

percentage of profit shared.

+ References

No definition available.

+ Details

Name:	chrs_PercentageOfGrossProfitsOnSales
Namespace Prefix:	chrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the period before the company can sell, transfer or make any short sale of common stock.

+ References

No definition available.

+ Details

Name:	chrs_PurchaseAgreementRestrictiveRequirementOnSellingTransferAndShortSaleOfCommonStock
Namespace Prefix:	chrs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_StockPurchaseAgreementSharesAgreedToBeIssued
Namespace Prefix:	chrs_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Value of shares agreed to be issued under stock purchase agreement in connection with the collaboration agreement.

+ References

No definition available.

+ Details

Name:	chrs_StockPurchaseAgreementSharesAgreedToBeIssuedValue
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents upfront and milestone payments.

+ References

No definition available.

+ Details

Name:	chrs_UpfrontAndMilestonePayment
Namespace Prefix:	chrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

+ Details

Name:	us-gaap_AccountsPayableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=chrs_BioeqIPAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=chrs_InnoventBiologicsSuzhouCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=chrs_BevacizumabLicensedProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=chrs_OptionExerciseFeeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=chrs_ExclusiveLicenseAndCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=chrs_AntiTigitAntibodyAndIl2CytokineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=chrs_JunshiBiosciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BalanceSheetLocationAxis=chrs_AccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=chrs_ToripalimabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: